MEK and the inhibitors: from bench to bedside.

Ibrutinib and novel BTK inhibitors in clinical development. J Hematol Oncol (2013) 1.92

Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics. J Hematol Oncol (2013) 1.59

Effects of MEK inhibitors GSK1120212 and PD0325901 in vivo using 10-plex quantitative proteomics and phosphoproteomics. Proteomics (2014) 1.54

Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers. Nature (2013) 1.52

Novel ALK inhibitors in clinical use and development. J Hematol Oncol (2015) 1.24

Notch signaling and EMT in non-small cell lung cancer: biological significance and therapeutic application. J Hematol Oncol (2014) 1.20

MEK inhibitors: a new class of chemotherapeutic agents with ocular toxicity. Eye (Lond) (2015) 1.18

Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia. J Hematol Oncol (2015) 1.17

ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development. J Hematol Oncol (2015) 1.14

B-Raf and the inhibitors: from bench to bedside. J Hematol Oncol (2013) 1.14

Selective inhibitors of nuclear export (SINE)--a novel class of anti-cancer agents. J Hematol Oncol (2014) 1.11

Emerging targeted therapies for melanoma treatment (review). Int J Oncol (2014) 1.10

Ten things you should know about protein kinases: IUPHAR Review 14. Br J Pharmacol (2015) 1.06

Selective anti-cancer agents as anti-aging drugs. Cancer Biol Ther (2013) 1.06

AFM13: a first-in-class tetravalent bispecific anti-CD30/CD16A antibody for NK cell-mediated immunotherapy. J Hematol Oncol (2015) 0.94

Phosphorylation of FADD by the kinase CK1α promotes KRASG12D-induced lung cancer. Sci Signal (2015) 0.93

Novel approaches in the management of pancreatic ductal adenocarcinoma: potential promises for the future. J Hematol Oncol (2015) 0.91

Stamping out RAF and MEK1/2 to inhibit the ERK1/2 pathway: an emerging threat to anticancer therapy. Oncogene (2015) 0.90

Programmed death 1 blockade, an Achilles heel for MMR-deficient tumors? J Hematol Oncol (2015) 0.90

Profiling of phospho-AKT, phospho-mTOR, phospho-MAPK and EGFR in non-small cell lung cancer. J Histochem Cytochem (2014) 0.90

Targeting drivers of melanoma with synthetic small molecules and phytochemicals. Cancer Lett (2015) 0.88

MEK1 is associated with carboplatin resistance and is a prognostic biomarker in epithelial ovarian cancer. BMC Cancer (2014) 0.88

MDM2 antagonists synergize broadly and robustly with compounds targeting fundamental oncogenic signaling pathways. Oncotarget (2014) 0.86

Novel agents for advanced pancreatic cancer. Oncotarget (2015) 0.86

Raf kinase inhibitory protein (RKIP) as a metastasis suppressor: regulation of signaling networks in cancer. Crit Rev Oncog (2014) 0.83

Mek inhibition results in marked antitumor activity against metastatic melanoma patient-derived melanospheres and in melanosphere-generated xenografts. J Exp Clin Cancer Res (2013) 0.82

Redirection of CD4+ and CD8+ T lymphocytes via an anti-CD3 × anti-CD19 bi-specific antibody combined with cytosine arabinoside and the efficient lysis of patient-derived B-ALL cells. J Hematol Oncol (2015) 0.82

Inhibition of B-Raf/MEK/ERK signaling suppresses DR5 expression and impairs response of cancer cells to DR5-mediated apoptosis and T cell-induced killing. Oncogene (2015) 0.82

Multiple Molecular Pathways in Melanomagenesis: Characterization of Therapeutic Targets. Front Oncol (2015) 0.82

SGK1 inhibits cellular apoptosis and promotes proliferation via the MEK/ERK/p53 pathway in colitis. World J Gastroenterol (2015) 0.81

Rational combination of MEK inhibitor and the STAT3 pathway modulator for the therapy in K-Ras mutated pancreatic and colon cancer cells. Oncotarget (2015) 0.80

Analysis of KRAS and BRAF genes mutation in the central nervous system metastases of non-small cell lung cancer. Clin Exp Med (2015) 0.80

The Mutant KRAS Gene Up-regulates BCL-XL Protein via STAT3 to Confer Apoptosis Resistance That Is Reversed by BIM Protein Induction and BCL-XL Antagonism. J Biol Chem (2015) 0.79

The MAPK ERK5, but not ERK1/2, inhibits the progression of monocytic phenotype to the functioning macrophage. Exp Cell Res (2014) 0.79

Roles of palmitoylation and the KIKK membrane-targeting motif in leukemogenesis by oncogenic KRAS4A. J Hematol Oncol (2015) 0.78

Trametinib: a MEK inhibitor for management of metastatic melanoma. Onco Targets Ther (2015) 0.78

Activated Ras as a Therapeutic Target: Constraints on Directly Targeting Ras Isoforms and Wild-Type versus Mutated Proteins. ISRN Oncol (2013) 0.78

Afatinib inhibits proliferation and invasion and promotes apoptosis of the T24 bladder cancer cell line. Exp Ther Med (2015) 0.78

Selumetinib, an Oral Anti-Neoplastic Drug, May Attenuate Cardiac Hypertrophy via Targeting the ERK Pathway. PLoS One (2016) 0.77

Evaluation of efficacy of a new MEK inhibitor, RO4987655, in human tumor xenografts by [(18)F] FDG-PET imaging combined with proteomic approaches. EJNMMI Res (2014) 0.77

Simultaneous perturbation of the MAPK and the PI3K/mTOR pathways does not lead to increased radiosensitization. Radiat Oncol (2015) 0.77

Sensitive methods for screening of the MEK1 gene mutations in patients with central nervous system metastases of non-small cell lung cancer. Clin Transl Oncol (2016) 0.77

A phase I/Ib study of trametinib (GSK1120212) alone and in combination with gemcitabine in Japanese patients with advanced solid tumors. Invest New Drugs (2015) 0.76

BAALC potentiates oncogenic ERK pathway through interactions with MEKK1 and KLF4. Leukemia (2015) 0.76

A new mitochondrial pool of cyclin E, regulated by Drp1, is linked to cell-density-dependent cell proliferation. J Cell Sci (2015) 0.76

Targeted inhibition of MEK1 by cobimetinib leads to differentiation and apoptosis in neuroblastoma cells. J Exp Clin Cancer Res (2015) 0.76

A first-in-human phase I study to evaluate the MEK1/2 inhibitor, cobimetinib, administered daily in patients with advanced solid tumors. Invest New Drugs (2016) 0.76

The dynamics of gene expression changes in a mouse model of oral tumorigenesis may help refine prevention and treatment strategies in patients with oral cancer. Oncotarget (2016) 0.75

Clinical, pharmacokinetic and pharmacodynamic data for the MEK1/2 inhibitor pimasertib in patients with advanced hematologic malignancies. Blood Cancer J (2015) 0.75

Enhanced anti-tumour activity of the combination of the novel MEK inhibitor WX-554 and the novel PI3K inhibitor WX-037. Cancer Chemother Pharmacol (2016) 0.75

Synthetic lethal interaction of cetuximab with MEK1/2 inhibition in NRAS-mutant metastatic colorectal cancer. Oncotarget (2016) 0.75

Antitumor activity of the MEK inhibitor trametinib on intestinal polyp formation in Apc(Δ716) mice involves stromal COX-2. Cancer Sci (2015) 0.75

Exosomal miRs in Lung Cancer: A Mathematical Model. PLoS One (2016) 0.75

KRAS and the Reality of Personalized Medicine in Non-small Cell Lung Cancer. Mol Med (2016) 0.75

Oncostatin M-induced cardiomyocyte dedifferentiation regulates the progression of diabetic cardiomyopathy through B-Raf/Mek/Erk signaling pathway. Acta Biochim Biophys Sin (Shanghai) (2016) 0.75

CEPP regimen (cyclophosphamide, etoposide, procarbazine and prednisone) as initial treatment for Hodgkin lymphoma patients presenting with severe abnormal liver function. Biomark Res (2014) 0.75

Targeting the ERK pathway for the treatment of Cushing's disease. Oncotarget (2016) 0.75

CDK4/6 or MAPK blockade enhances efficacy of EGFR inhibition in oesophageal squamous cell carcinoma. Nat Commun (2017) 0.75

Expression of Death Receptor 4 Is Positively Regulated by MEK/ERK/AP-1 Signaling and Suppressed upon MEK Inhibition. J Biol Chem (2016) 0.75

Recent advances and novel agents for FLT3 mutated acute myeloid leukemia. Stem Cell Investig (2014) 0.75

Genomic Characterization of Poorly Differentiated Neuroendocrine Carcinoma in a Pediatric Patient. J Pediatr Hematol Oncol (2016) 0.75

Metallothionein 1H (MT1H) functions as a tumor suppressor in hepatocellular carcinoma through regulating Wnt/β-catenin signaling pathway. BMC Cancer (2017) 0.75

Synergistic cooperation between ABT-263 and MEK1/2 inhibitor: effect on apoptosis and proliferation of acute myeloid leukemia cells. Oncotarget (2015) 0.75

Autonomous and Non-autonomous Defects Underlie Hypertrophic Cardiomyopathy in BRAF-Mutant hiPSC-Derived Cardiomyocytes. Stem Cell Reports (2016) 0.75

ETS-targeted therapy: can it substitute for MEK inhibitors? Clin Transl Med (2017) 0.75

Paradoxical activation of MEK/ERK signaling induced by B-Raf inhibition enhances DR5 expression and DR5 activation-induced apoptosis in Ras-mutant cancer cells. Sci Rep (2016) 0.75

A phase I dose-escalation study of TAK-733, an investigational oral MEK inhibitor, in patients with advanced solid tumors. Invest New Drugs (2016) 0.75

Phase I and pharmacokinetics/pharmacodynamics study of the MEK inhibitor RO4987655 in Japanese patients with advanced solid tumors. Invest New Drugs (2015) 0.75

A phase I dose-escalation study of Selumetinib in combination with Erlotinib or Temsirolimus in patients with advanced solid tumors. Invest New Drugs (2017) 0.75

Clinical and Morphologic Characteristics of MEK Inhibitor-Associated Retinopathy: Differences from Central Serous Chorioretinopathy. Ophthalmology (2017) 0.75

Mutations of the BRAF gene in human cancer. Nature (2002) 65.42

Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med (2011) 45.46

The protein kinase family: conserved features and deduced phylogeny of the catalytic domains. Science (1988) 35.59

Mammalian MAP kinase signalling cascades. Nature (2001) 18.89

Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol Rev (2001) 13.15

Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med (2012) 11.72

Requirement of JNK for stress-induced activation of the cytochrome c-mediated death pathway. Science (2000) 8.56

Independent human MAP-kinase signal transduction pathways defined by MEK and MKK isoforms. Science (1995) 7.87

Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability. Genes Dev (2000) 6.54

RAS oncogenes: weaving a tumorigenic web. Nat Rev Cancer (2011) 6.45

Signal transduction by the c-Jun N-terminal kinase (JNK)--from inflammation to development. Curr Opin Cell Biol (1998) 6.28

Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor. Clin Cancer Res (2007) 5.59

Activation and signaling of the p38 MAP kinase pathway. Cell Res (2005) 5.48

ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation. Nat Cell Biol (2008) 5.19

Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study. Lancet Oncol (2012) 5.16

Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol (2008) 4.82

Identification of a dual specificity kinase that activates the Jun kinases and p38-Mpk2. Science (1995) 4.74

BMK1/ERK5 regulates serum-induced early gene expression through transcription factor MEF2C. EMBO J (1997) 4.51

MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. Lancet Oncol (2013) 4.26

Liver tumor development. c-Jun antagonizes the proapoptotic activity of p53. Cell (2003) 3.92

Components of a new human protein kinase signal transduction pathway. J Biol Chem (1995) 3.78

Characterization of the structure and function of a new mitogen-activated protein kinase (p38beta). J Biol Chem (1996) 3.63

Characterization of the structure and function of a novel MAP kinase kinase (MKK6). J Biol Chem (1996) 3.63

Activation of the protein kinase ERK5/BMK1 by receptor tyrosine kinases. Identification and characterization of a signaling pathway to the nucleus. J Biol Chem (1999) 3.42

GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition. Clin Cancer Res (2011) 3.36

Mechanism of p38 MAP kinase activation in vivo. Genes Dev (2003) 3.36

Initiation of a G2/M checkpoint after ultraviolet radiation requires p38 kinase. Nature (2001) 3.25

Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. N Engl J Med (2013) 3.21

JNK-mediated BIM phosphorylation potentiates BAX-dependent apoptosis. Neuron (2003) 2.86

Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial. Lancet Oncol (2012) 2.86

Bmk1/Erk5 is required for cell proliferation induced by epidermal growth factor. Nature (1998) 2.62

Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma. Clin Cancer Res (2011) 2.52

Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. Cancer Res (2008) 2.48

Tumour cell survival signalling by the ERK1/2 pathway. Cell Death Differ (2008) 2.44

Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies. J Clin Oncol (2005) 2.32

The discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901. Bioorg Med Chem Lett (2008) 2.28

Isolation of MEK5 and differential expression of alternatively spliced forms. J Biol Chem (1995) 2.23

Integrating the MAP kinase signal into the G1 phase cell cycle machinery. Bioessays (2000) 2.22

Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study. Lancet Oncol (2012) 2.14

Erk5 null mice display multiple extraembryonic vascular and embryonic cardiovascular defects. Proc Natl Acad Sci U S A (2002) 2.11

ERK5 is a novel type of mitogen-activated protein kinase containing a transcriptional activation domain. Mol Cell Biol (2000) 2.02

Phase II efficacy and pharmacogenomic study of Selumetinib (AZD6244; ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma with or without follicular elements. Clin Cancer Res (2012) 2.02

Regulation of cellular functions by the ERK5 signalling pathway. Cell Signal (2006) 1.98

A phase II study of PD-0325901, an oral MEK inhibitor, in previously treated patients with advanced non-small cell lung cancer. Clin Cancer Res (2010) 1.95

MEK5 overexpression is associated with metastatic prostate cancer, and stimulates proliferation, MMP-9 expression and invasion. Oncogene (2003) 1.83

Recent progress in targeting the Raf/MEK/ERK pathway with inhibitors in cancer drug discovery. Curr Opin Pharmacol (2005) 1.79

SEK1 deficiency reveals mitogen-activated protein kinase cascade crossregulation and leads to abnormal hepatogenesis. Proc Natl Acad Sci U S A (1998) 1.78

Blockade of the MEK/ERK signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic anti-myeloma activity in vitro and in vivo. Br J Haematol (2010) 1.73

A phase II, open-label, randomized study to assess the efficacy and safety of AZD6244 (ARRY-142886) versus pemetrexed in patients with non-small cell lung cancer who have failed one or two prior chemotherapeutic regimens. J Thorac Oncol (2010) 1.72

Cloning and characterization of MEK6, a novel member of the mitogen-activated protein kinase kinase cascade. J Biol Chem (1996) 1.68

p38 MAP kinase's emerging role as a tumor suppressor. Adv Cancer Res (2004) 1.64

Erk5 participates in neuregulin signal transduction and is constitutively active in breast cancer cells overexpressing ErbB2. Mol Cell Biol (2002) 1.64

Identification of substrates and regulators of the mitogen-activated protein kinase ERK5 using chimeric protein kinases. J Biol Chem (1998) 1.64

Crystal structures of MEK1 binary and ternary complexes with nucleotides and inhibitors. Biochemistry (2009) 1.63

A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens. Invest New Drugs (2010) 1.62

Novel role for JNK as a stress-activated Bcl2 kinase. J Biol Chem (2001) 1.60

The hinge-helix 1 region of peroxisome proliferator-activated receptor gamma1 (PPARgamma1) mediates interaction with extracellular signal-regulated kinase 5 and PPARgamma1 transcriptional activation: involvement in flow-induced PPARgamma activation in endothelial cells. Mol Cell Biol (2004) 1.59

Intermittent administration of MEK inhibitor GDC-0973 plus PI3K inhibitor GDC-0941 triggers robust apoptosis and tumor growth inhibition. Cancer Res (2011) 1.56

Current management and novel agents for malignant melanoma. J Hematol Oncol (2012) 1.53

Phase II study of the mitogen-activated protein kinase 1/2 inhibitor selumetinib in patients with advanced hepatocellular carcinoma. J Clin Oncol (2011) 1.52

Regulation of cardiac hypertrophy in vivo by the stress-activated protein kinases/c-Jun NH(2)-terminal kinases. J Clin Invest (1999) 1.50

A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy. Invest New Drugs (2011) 1.49

MEKK3 directly regulates MEK5 activity as part of the big mitogen-activated protein kinase 1 (BMK1) signaling pathway. J Biol Chem (1999) 1.47

Antitumor activities of JTP-74057 (GSK1120212), a novel MEK1/2 inhibitor, on colorectal cancer cell lines in vitro and in vivo. Int J Oncol (2011) 1.46

Conserved docking site is essential for activation of mammalian MAP kinase kinases by specific MAP kinase kinase kinases. Mol Cell (2005) 1.45

The p38 kinases MKK4 and MKK6 suppress metastatic colonization in human ovarian carcinoma. Cancer Res (2006) 1.43

Dysregulation of JAK-STAT pathway in hematological malignancies and JAK inhibitors for clinical application. Biomark Res (2013) 1.43

First-in-human, phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of RO5126766, a first-in-class dual MEK/RAF inhibitor in patients with solid tumors. Clin Cancer Res (2012) 1.39

MEKK2 associates with the adapter protein Lad/RIBP and regulates the MEK5-BMK1/ERK5 pathway. J Biol Chem (2000) 1.39

RDEA119/BAY 869766: a potent, selective, allosteric inhibitor of MEK1/2 for the treatment of cancer. Cancer Res (2009) 1.38

RAF protein-serine/threonine kinases: structure and regulation. Biochem Biophys Res Commun (2010) 1.37

Involvement of the p38 mitogen-activated protein kinase cascade in hepatocellular carcinoma. Cancer (2003) 1.32

Homozygous deletion of MKK4 in ovarian serous carcinoma. Cancer Biol Ther (2006) 1.32

MEK1/2 inhibitors AS703026 and AZD6244 may be potential therapies for KRAS mutated colorectal cancer that is resistant to EGFR monoclonal antibody therapy. Cancer Res (2010) 1.26

Current management and prognostic features for gastrointestinal stromal tumor (GIST). Exp Hematol Oncol (2012) 1.23

The role of scaffold proteins in MEK/ERK signalling. Biochem Soc Trans (2006) 1.22

Discovery of TAK-733, a potent and selective MEK allosteric site inhibitor for the treatment of cancer. Bioorg Med Chem Lett (2011) 1.20

Antitumor effects of the investigational selective MEK inhibitor TAK733 against cutaneous and uveal melanoma cell lines. Mol Cancer (2012) 1.18

MEK1 mutations, but not ERK2 mutations, occur in melanomas and colon carcinomas, but none in thyroid carcinomas. Cell Cycle (2009) 1.17

Impaired CD28-mediated interleukin 2 production and proliferation in stress kinase SAPK/ERK1 kinase (SEK1)/mitogen-activated protein kinase kinase 4 (MKK4)-deficient T lymphocytes. J Exp Med (1997) 1.15

Targeted deletion of MKK4 in cancer cells: a detrimental phenotype manifests as decreased experimental metastasis and suggests a counterweight to the evolution of tumor-suppressor loss. Cancer Res (2006) 1.11

Comprehensive analysis of homeobox genes in Hodgkin lymphoma cell lines identifies dysregulated expression of HOXB9 mediated via ERK5 signaling and BMI1. Blood (2007) 1.09

Polo-like kinase 1 as target for cancer therapy. Exp Hematol Oncol (2012) 1.09

MEK inhibitor PD0325901 significantly reduces the growth of papillary thyroid carcinoma cells in vitro and in vivo. Mol Cancer Ther (2010) 1.08

PB1 domain-dependent signaling complex is required for extracellular signal-regulated kinase 5 activation. Mol Cell Biol (2006) 1.07

Extracellular signal-regulated kinase 2-dependent phosphorylation induces cytoplasmic localization and degradation of p21Cip1. Mol Cell Biol (2009) 1.06

Regulation of c-Fos and Fra-1 by the MEK5-ERK5 pathway. Genes Cells (2003) 1.06

HGF mediates cell proliferation of human mesothelioma cells through a PI3K/MEK5/Fra-1 pathway. Am J Respir Cell Mol Biol (2007) 1.05

Phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of the MEK inhibitor RO4987655 (CH4987655) in patients with advanced solid tumors. Clin Cancer Res (2012) 1.03

Progress towards therapeutic small molecule MEK inhibitors for use in cancer therapy. Curr Top Med Chem (2005) 0.97

c-Jun NH2-terminal kinase is required for lineage-specific differentiation but not stem cell self-renewal. Mol Cell Biol (2010) 0.97

Bridging the gap between preclinical and clinical studies using pharmacokinetic-pharmacodynamic modeling: an analysis of GDC-0973, a MEK inhibitor. Clin Cancer Res (2012) 0.95

MicroRNAs and toll-like receptor/interleukin-1 receptor signaling. J Hematol Oncol (2012) 0.95

Fully activated MEK1 exhibits compromised affinity for binding of allosteric inhibitors U0126 and PD0325901. Biochemistry (2011) 0.94

Requirement of the MEK5-ERK5 pathway for neural differentiation in Xenopus embryonic development. EMBO Rep (2005) 0.90

Overwhelming response to Dabrafenib in a patient with double BRAF mutation (V600E; V600M) metastatic malignant melanoma. J Hematol Oncol (2012) 0.88

Design and synthesis of novel allosteric MEK inhibitor CH4987655 as an orally available anticancer agent. Bioorg Med Chem Lett (2011) 0.87

Antitumour activity of a potent MEK inhibitor RDEA119/BAY 869766 combined with rapamycin in human orthotopic primary pancreatic cancer xenografts. BMC Cancer (2010) 0.87

Expression of the phosphorylated MEK5 protein is associated with TNM staging of colorectal cancer. BMC Cancer (2012) 0.85

A phase I dose-finding, safety and tolerability study of AZD8330 in patients with advanced malignancies. Eur J Cancer (2013) 0.84

The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia. Blood (2010) 5.95

Somatic Mutations and Clonal Hematopoiesis in Aplastic Anemia. N Engl J Med (2015) 3.42

Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents. J Hematol Oncol (2010) 2.94

Isolation and characterization of human umbilical cord mesenchymal stem cells with hematopoiesis-supportive function and other potentials. Haematologica (2006) 2.75

Critical Role of STAT5 transcription factor tetramerization for cytokine responses and normal immune function. Immunity (2012) 2.16

Nuclear miRNA regulates the mitochondrial genome in the heart. Circ Res (2012) 1.95

Ibrutinib and novel BTK inhibitors in clinical development. J Hematol Oncol (2013) 1.92

Fetal mouse phthalate exposure shows that Gonocyte multinucleation is not associated with decreased testicular testosterone. Toxicol Sci (2007) 1.75

Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics. J Hematol Oncol (2013) 1.59

Current management and novel agents for malignant melanoma. J Hematol Oncol (2012) 1.53

Dysregulation of JAK-STAT pathway in hematological malignancies and JAK inhibitors for clinical application. Biomark Res (2013) 1.43

First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib. J Hematol Oncol (2010) 1.40

Novel CD20 monoclonal antibodies for lymphoma therapy. J Hematol Oncol (2012) 1.30

Reversal in multidrug resistance by magnetic nanoparticle of Fe3O4 loaded with adriamycin and tetrandrine in K562/A02 leukemic cells. Int J Nanomedicine (2008) 1.29

New clinical developments in histone deacetylase inhibitors for epigenetic therapy of cancer. J Hematol Oncol (2009) 1.24

Current management and prognostic features for gastrointestinal stromal tumor (GIST). Exp Hematol Oncol (2012) 1.23

p38 mitogen-activated protein kinase plays an inhibitory role in hepatic lipogenesis. J Biol Chem (2006) 1.23

Novel agents and regimens for acute myeloid leukemia: 2009 ASH annual meeting highlights. J Hematol Oncol (2010) 1.18

STAT inhibitors for cancer therapy. J Hematol Oncol (2013) 1.16

Recent advances and novel agents for gastrointestinal stromal tumor (GIST). J Hematol Oncol (2012) 1.16

Treatment-induced oxidative stress and cellular antioxidant capacity determine response to bortezomib in mantle cell lymphoma. Clin Cancer Res (2011) 1.14

Human parvovirus B19 causes cell cycle arrest of human erythroid progenitors via deregulation of the E2F family of transcription factors. J Clin Invest (2010) 1.14

B-Raf and the inhibitors: from bench to bedside. J Hematol Oncol (2013) 1.14

Ingestion of an isothiocyanate metabolite from cruciferous vegetables inhibits growth of human prostate cancer cell xenografts by apoptosis and cell cycle arrest. Carcinogenesis (2004) 1.13

Targeting cell cycle machinery as a molecular mechanism of sulforaphane in prostate cancer prevention. Int J Oncol (2004) 1.12

Dietary nitrate and nitrite modulate blood and organ nitrite and the cellular ischemic stress response. Free Radic Biol Med (2009) 1.12

Phenylhexyl isothiocyanate inhibits histone deacetylases and remodels chromatins to induce growth arrest in human leukemia cells. Int J Oncol (2006) 1.11

Cardiopulmonary resuscitation: outcome and its predictors among hospitalized adult patients in Pakistan. Int J Emerg Med (2008) 1.08

A meta-analysis of CAG (cytarabine, aclarubicin, G-CSF) regimen for the treatment of 1029 patients with acute myeloid leukemia and myelodysplastic syndrome. J Hematol Oncol (2011) 0.99

Microarray-based characterization of a colony assay used to investigate endothelial progenitor cells and relevance to endothelial function in humans. Arterioscler Thromb Vasc Biol (2009) 0.99

Testicular gene expression profiling following prepubertal rat mono-(2-ethylhexyl) phthalate exposure suggests a common initial genetic response at fetal and prepubertal ages. Toxicol Sci (2006) 0.99

P-loop mutations and novel therapeutic approaches for imatinib failures in chronic myeloid leukemia. J Hematol Oncol (2008) 0.95

Drug overdose: a wake up call! Experience at a tertiary care centre in Karachi, Pakistan. J Pak Med Assoc (2008) 0.95

Comparison of safety and toxicity of liposomal doxorubicin vs. conventional anthracyclines: a meta-analysis. Exp Hematol Oncol (2012) 0.94

Sox4 cooperates with PU.1 haploinsufficiency in murine myeloid leukemia. Blood (2011) 0.92

Side effects related to cancer treatment: CASE 2. Splenic rupture following pegfilgrastim. J Clin Oncol (2005) 0.92

Severe toxicity of skin rash, fever and diarrhea associated with imatinib: case report and review of skin toxicities associated with tyrosine kinase inhibitors. Drug Des Devel Ther (2009) 0.91

A randomized, double-blind, placebo-controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate-1 risk myelodysplastic syndrome receiving lenalidomide. J Hematol Oncol (2012) 0.91

CD146+ T lymphocytes are increased in both the peripheral circulation and in the synovial effusions of patients with various musculoskeletal diseases and display pro-inflammatory gene profiles. Cytometry B Clin Cytom (2010) 0.89

Phenylhexyl isothiocyanate has dual function as histone deacetylase inhibitor and hypomethylating agent and can inhibit myeloma cell growth by targeting critical pathways. J Hematol Oncol (2008) 0.89

Phase I study of temozolomide in relapsed/refractory acute leukemia. J Clin Oncol (2002) 0.86

APACHE II scores as predictors of cardio pulmonary resuscitation outcome: Evidence from a tertiary care institute in a low-income country. Saudi J Anaesth (2012) 0.85

The phenylhexyl isothiocyanate induces apoptosis and inhibits leukemia cell growth in vivo. Oncol Rep (2006) 0.84

miR-222 contributes to sex-dimorphic cardiac eNOS expression via ets-1. Physiol Genomics (2013) 0.84

Palladium-catalyzed allylic alkylation of simple ketones with allylic alcohols and its mechanistic study. Angew Chem Int Ed Engl (2014) 0.84

Severe toxicity following induction chemotherapy for acute myelogenous leukemia in a patient with Werner's syndrome. Leuk Lymphoma (2005) 0.84

Knowledge and awareness about breast cancer and its early symptoms among medical and non-medical students of Southern Punjab, Pakistan. Asian Pac J Cancer Prev (2015) 0.83

High fat diet reduces the expression of glutathione peroxidase 3 in mouse prostate. Prostate (2011) 0.82

PET scan-positive cat scratch disease in a patient with T cell lymphoblastic lymphoma. Leuk Res (2005) 0.80

Efficient palladium-catalyzed asymmetric allylic alkylation of ketones and aldehydes. Org Biomol Chem (2011) 0.80

Germline mutations predisposing to non-small cell lung cancer. Fam Cancer (2015) 0.80

Deficient histone acetylation in acute leukemia and the correction by an isothiocyanate. Acta Haematol (2009) 0.79

T-cryptantigen (TCA) activation in sever pneumonia complicated with multiple organ failure. Transfus Apher Sci (2010) 0.79

Acute promyelocytic leukemia with tetraploid karyotype: first report in the Western hemisphere and update of previous reports. Leuk Res (2011) 0.79

C-N bond cleavage of allylic amines via hydrogen bond activation with alcohol solvents in Pd-catalyzed allylic alkylation of carbonyl compounds. J Am Chem Soc (2011) 0.79

[Coblation-assisting uvulopalatopharyngoplasty combining coblation-channeling of the tongue for patients with severe OSAHS]. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi (2012) 0.78

Novel biomarkers for diagnosis, prognosis, targeted therapy and clinical trials. Biomark Res (2013) 0.78

Coexistence of inversion 16 and the Philadelphia chromosome in patients with acute myelogenous leukemia. Leuk Lymphoma (2002) 0.77

Novel influenza A (H1N1) in patients with hematologic malignancies. J Clin Oncol (2009) 0.77

[Modulation of histone acetylation and induction of apoptosis in SMMC-7721 cells by phenylhexyl isothiocyanate]. Zhonghua Zhong Liu Za Zhi (2010) 0.76

Very late relapse of chronic myelogenous leukemia after allogeneic bone marrow transplantation. Leuk Res (2009) 0.76

Prospective evaluation of 2009 H1N1 influenza A in patients admitted with fever to an oncology unit. Infect Control Hosp Epidemiol (2011) 0.76

Hydrogen-bond-activated palladium-catalyzed allylic alkylation via allylic alkyl ethers: challenging leaving groups. Org Lett (2014) 0.76

t(3;9;22) 3-way chromosome translocation in chronic myeloid leukemia is associated with poor prognosis. Cancer Invest (2009) 0.76

Syncope: experience at a tertiary care hospital in Karachi, Pakistan. Int J Emerg Med (2008) 0.75

Sweet fruit from a poisonous kiss. J Hematol Oncol (2010) 0.75

Journal of hematology & oncology: a journal open to all. J Hematol Oncol (2008) 0.75

1,3-Bis(3-methyl-phen-yl)thio-urea: triclinic polymorph. Acta Crystallogr Sect E Struct Rep Online (2009) 0.75

Phenotypic and functional characterization of a mouse model of targeted Pig-a deletion in hematopoietic cells. Haematologica (2009) 0.75

Management of mantle cell leukemia with cardiac involvement leading to cardiogenic shock. Front Med (2014) 0.75

Acute myelogenous leukemia following irinotecan-based chemotherapy for adenocarcinoma of the small intestine. Leuk Lymphoma (2007) 0.75

Evaluation of temozolomide in patients with myelodysplastic syndrome. Leuk Lymphoma (2004) 0.75

Severe imatinib-associated muscle edema in patients with chronic myelogenous leukemia and marked leukocytosis. Leuk Lymphoma (2008) 0.75

Preventive medicine practices by primary care providers in Karachi. J Coll Physicians Surg Pak (2008) 0.75

Long-term follow-up of high-dose mitoxantrone-based induction therapy for patients with newly-diagnosed acute myelogenous leukemia. Twelve year results from a single institution. Leuk Lymphoma (2006) 0.75

Highly efficient asymmetric Michael addition of aldehyde to nitroolefin using perhydroindolic acid as a chiral organocatalyst. Org Biomol Chem (2012) 0.75

O2(⋅-) and H2O2-Mediated Disruption of Fe Metabolism Causes the Differential Susceptibility of NSCLC and GBM Cancer Cells to Pharmacological Ascorbate. Cancer Cell (2017) 0.75

P-stereogenic PNP pincer-Pd catalyzed intramolecular hydroamination of amino-1,3-dienes. Org Biomol Chem (2015) 0.75

[Preliminary clinical investigation of coblation-assisted functional endoscopic sinus surgery for chronic sinusitis and nasal polyps]. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi (2011) 0.75

[Low-temperature plasma assisted via mouth for surgery treating styloid process syndrome]. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi (2012) 0.75

The Conundrum of "Warfarin Hypersensitivity": Prolonged Partial Thromboplastin Time From Factor IX Propeptide Mutation. Am J Ther (2016) 0.75

[Advances in treatment of congenital posterior choanal atresia]. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi (2016) 0.75

[Coblation for benign hyperplasia of tongue base under endoscope]. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi (2009) 0.75

1270: THE EFFECT OF ATTENDING PHYSICIAN CONTINUITY OF CARE ON PATIENTS ADMITTED TO THE INTENSIVE CARE UNIT. Crit Care Med (2016) 0.75

[Clinical observation of coblation under endoscopy on epiglottis cyst]. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi (2014) 0.75

Iridium-catalyzed allyl-allyl cross-coupling of allylic carbonates with (E)-1,3-diarylpropenes. Chem Commun (Camb) (2015) 0.75

[EFFECTIVENESS OF POSTERIOR UNILATERAL TRANSPEDICULAR DEBRIDEMENT, BONE GRAFT FUSION, AND PEDICLE SCREW FIXATION FOR THORACOLUMBAL TUBERCULOSIS]. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi (2015) 0.75

[Expression of BDNF and trk B in the cochleas of the aged rats]. Lin Chuang Er Bi Yan Hou Ke Za Zhi (2006) 0.75

[Revaluvation of UPPP and the pharynx in patients with snoring anatomy]. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi (2015) 0.75

[Coblation-channelling for the tongue]. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi (2014) 0.75

Asymmetric tandem reactions of N-sulfonylimines and α,β-unsaturated aldehydes: an alternative reaction pathway to that of using saturated aldehydes. Chem Commun (Camb) (2014) 0.75

[Investigation of reoperation after failure of UPPP]. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi (2009) 0.75

Pd-catalyzed asymmetric allylic amination using easily accessible metallocenyl P,N-ligands. Org Biomol Chem (2015) 0.75

Asymmetric domino reaction of cyclic N-sulfonylimines and simple aldehydes with trans-perhydroindolic acid as an organocatalyst. Org Lett (2014) 0.75

Brain natriuretic peptide, systolic and diastolic blood pressures. J Ayub Med Coll Abbottabad (2009) 0.75